SCHEMBL1480940

SCHEMBL1480940

CCn1cc(-c2ccc(Cl)cc2Cl)nc1/C=C/c1cc(-c2cccc(O)c2)ccc1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
ATM Q13315 1/20 0.41
FYN P06241 1/20 0.34
TDP1 Q9NUW8 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
ALDH1A1 P00352 2/20 0.34
DPP4 P27487 2/20 0.34
DPP8 Q6V1X1 2/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34
ALOX12 P18054 1/20 0.34
HTT P42858 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 3/20 0.33
HDAC8 Q9BY41 1/20 0.33
CRHR1 P34998 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1480942 1.00 MEN1 (0.41) MEN1KMT2ANPC1RAB9AATM
SCHEMBL1481879 0.92 MEN1 (0.39) MEN1KMT2ANPC1RAB9AATM
SCHEMBL1481881 0.92 MEN1 (0.39) MEN1KMT2ANPC1RAB9AATM
SCHEMBL1481672 0.86 MAPT (0.35) MEN1KMT2ASMN1; SMN2DPP4DPP8
SCHEMBL1481670 0.86 MAPT (0.35) MEN1KMT2ASMN1; SMN2DPP4DPP8
SCHEMBL1481420 0.85 LMNA (0.35) MEN1KMT2ASMN1; SMN2DPP4DPP8
SCHEMBL1481423 0.85 LMNA (0.35) MEN1KMT2ASMN1; SMN2DPP4DPP8
SCHEMBL1481911 0.84 ACHE (0.39) MEN1KMT2ANPC1RAB9AATM
SCHEMBL1481908 0.84 ACHE (0.39) MEN1KMT2ANPC1RAB9AATM
SCHEMBL1481343 0.84 FFAR4 (0.40) ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ MEN1 3467/4885KMT2A 1996/4885NPC1 3792/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ MEN1 3467/4885KMT2A 1996/4885NPC1 3792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.